{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:25:19Z","timestamp":1792409119260,"version":"4.4.0"},"reference-count":64,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid maintenance treatment with oral methadone or sublingual buprenorphine is the first-line treatment in opioid dependence. Three novel long-acting buprenorphine formulations have been approved or will be available soon: for subcutaneous weekly and monthly application, the depot formulations CAM 2038 (Buvidal\u00ae), the monthly depot formulation RBP-6000 (Sublocade\u2122), and a 6-month buprenorphine implant (Probuphine\u2122). Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.<\/jats:p>","DOI":"10.1055\/a-1298-4508","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T02:51:44Z","timestamp":1605840704000},"page":"18-22","source":"Crossref","is-referenced-by-count":23,"title":["Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update"],"prefix":"10.1055","volume":"54","author":[{"given":"Michael","family":"Soyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/add.12551","article-title":"The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study","volume":"109","author":"L Degenhardt","year":"2014","journal-title":"Addiction"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"M A Schuckit","year":"2016","journal-title":"N Engl J Med"},{"key":"ref3","first-page":"577","article-title":"Gebrauch von Alkohol, Tabak, illegalen Drogen und Medikamenten","volume":"116","author":"J Atzendorf","year":"2019","journal-title":"Dtsch \u00c4rzteblatt"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"J Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1360-0443.2005.01012.x","article-title":"Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring","volume":"100","author":"A T McLellan","year":"2005","journal-title":"Addiction"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/add.14059","article-title":"Associations between methadone maintenance treatment and crime: A 17-year longitudinal cohort study of Canadian provincial offenders","volume":"113","author":"A Russolillo","year":"2018","journal-title":"Addiction"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jsat.2004.10.013","article-title":"The duration and correlates of addiction and treatment careers","volume":"28","author":"M L Dennis","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0376-8716(00)00211-8","article-title":"Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study","volume":"62","author":"M Gossop","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12051","article-title":"Pharmacological maintenance treatments of opiate addiction","volume":"77","author":"J Bell","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"CD004147","DOI":"10.1002\/14651858.CD004147.pub4","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","volume":"10","author":"L Amato","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"CD002207","DOI":"10.1002\/14651858.CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"R P Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000468518","article-title":"Six-year outcome of opioid maintenance treatment in heroin-dependent patients: Results from a naturalistic study in a nationally representative sample","volume":"23","author":"M Soyka","year":"2017","journal-title":"Eur Addict Res"},{"key":"ref14","first-page":"177","volume-title":"Opioide","author":"M Walter","year":"2019"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies: Tackling the opioid-overdose epidemic","volume":"370","author":"N D Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(01)06529-1","article-title":"Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study","volume":"358","author":"J Rehm","year":"2001","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","article-title":"Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine prescribing as treatment for refractory heroin addiction","volume":"207","author":"J Strang","year":"2015","journal-title":"Br J Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1360-0443.2007.02029.x","article-title":"The impact of treatment on 3 years\u2019 outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS)","volume":"103","author":"M Teesson","year":"2007","journal-title":"Addiction"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study","volume":"2","author":"J Kimber","year":"2015","journal-title":"Lancet Psychiat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2005.05.010","article-title":"Cycling in and out of treatment; participation in methadone treatment in NSW, 1990\u20132002","volume":"81","author":"J Bell","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e0139942","DOI":"10.1371\/journal.pone.0139942","article-title":"Investigation of repeat client drop-out and re-enrolment cycles in fourteen methadone maintenance treatment clinics in Guangdong, China","volume":"10","author":"L Zhang","year":"2015","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1360-0443.2010.03014.x","article-title":"The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician\u2019s perspective","volume":"105","author":"J Bell","year":"2010","journal-title":"Addiction"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"C Timko","year":"2016","journal-title":"J Addict Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"A Fareed","year":"2012","journal-title":"J Addict Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"M K Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"M K Greenwald","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine","volume":"93","author":"J J Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Y I Hser","year":"2016","journal-title":"Addiction"},{"key":"ref30","first-page":"8","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Y I Hser","year":"2014","journal-title":"Addiction"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"J Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"J Bell","year":"2009","journal-title":"Addiction"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J069v20n04_02","article-title":"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM)","volume":"20","author":"R L Deamer","year":"2001","journal-title":"J Addict Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","article-title":"Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation-results from a controlled clinical trial","volume":"14","author":"H Wieneke","year":"2009","journal-title":"Eur J Med Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Goodman-Meza. Depot buprenorphine in the management of opioid use disorder","volume":"10","author":"W Ling","year":"2019","journal-title":"From development to implementation. Subst Abuse Rehabil"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"M A Coe","year":"2019","journal-title":"J Addict Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomised clinical trial","volume":"74","author":"S L Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study","volume":"34","author":"M Albayaty","year":"2017","journal-title":"Adv Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","article-title":"Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder","volume":"78","author":"C Haasen","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorhpine depot formulations vs daily sublingual burpenorphine with naloxone for treatment of opioid use disorder: a randomized clinical Trial","volume":"178","author":"M R Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Longtime safety of weekly and monthly subcutaneous Buprenorphindepot (CAM 2038) in the treatment of adult out-patients with opiod use disorders","volume":"114","author":"M Frost","year":"2019","journal-title":"Addiction"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"C M Laffont","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40262-014-0155-0","article-title":"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence","volume":"53","author":"A F Nasser","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"B R Haight","year":"2019","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (bup-xr) double-blind, placebo-controlled, multicenter, phase study","volume":"13","author":"W Ling","year":"2019","journal-title":"J Addict Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2045125316681984","article-title":"Probuphine\u00ae (buprenorphine implant): a promising candidate in opioid dependence","volume":"7","author":"P Barnwal","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/DDDT.S109331","article-title":"New developments in managing opioid addiction: impact of a subdermal buprenorphine implant","volume":"11","author":"M Itzoe","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2009.03.008","article-title":"Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence","volume":"103","author":"J White","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial","volume":"304","author":"W Ling","year":"2010","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"R N Rosenthal","year":"2013","journal-title":"Addiction"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: A randomized clinical trial","volume":"316","author":"R N Rosenthal","year":"2016","journal-title":"JAMA"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41380-018-0329-5","article-title":"The importance of buprenorphine research in the opioid crisis","volume":"24","author":"S A Pendergrass","year":"2019","journal-title":"Mol Psychiatry"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0269881118756015","article-title":"Buprenorphine alone or with naloxone: Which is safer?","volume":"32","author":"E Kelty","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref55","first-page":"115","article-title":"Clinical applications of burprenorphine depot injection for opioid use disorder","author":"S Allikmets","year":"2020","journal-title":"Addiction"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management","volume":"94","author":"S R Kenney","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"CN E Tompkins","year":"2019","journal-title":"J Subst Abuse Treatment"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-019-0296-4","article-title":"Prolonged-release opioid agonist therapy: qualitative study exploring patients views of 1-week","volume":"16","author":"J Neale","year":"2019","journal-title":"1-month and 6-month buprenorphine formulations. Harm Reduct J"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"M Gilman","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: from development to implementation","volume":"10","author":"W Ling","year":"2019","journal-title":"Subst Abuse Rehabil"},{"key":"ref61","first-page":"119","article-title":"Covid-19 and substitution","volume":"22","author":"M Soyka","year":"2020","journal-title":"Suchtmed"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17425247.2019.1649252","article-title":"What place for prolonged-release buprenorphine depot-formulation buvidal in the treatment arsenal if opioid dependence? Insights from the French experience on buprenorphine","volume":"16","author":"F Vorspan","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/add.14941","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","volume":"115","author":"B Larance","year":"2019","journal-title":"Addiction"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107586","article-title":"Predictors of availability of long-acting medication for opioid use disorder","author":"C L Shover","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2019.1706552","article-title":"Optimal dose of buprenorphine in opioid use disorder treatment: A review of pharmacodynamic and efficacy data","author":"P Hjelstr\u00f6m","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review","volume":"19","author":"E F McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.xphs.2017.10.035","article-title":"A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions of buprenorphine after subcutaneous administration of CAM2038 with perpetrators of CYP3A4","volume":"107","author":"T Liu","year":"2018","journal-title":"J Pharm Sci"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1298-4508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T21:59:45Z","timestamp":1618437585000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1298-4508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":64,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,7]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1298-4508","relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}